Female Reproductive & Breast

Nipple discharge: workup

Clinical Overview and When to Suspect Pathologic Nipple Discharge

— Bilateral, multi-ductal, only with expression/squeezing

— Color: white, yellow, green, brown, gray — but not bloody and not clear serous

— Associated with nipple stimulation, chest wall trauma, ill-fitting bras, OCPs, antipsychotics, SSRIs, opioids

— Spontaneous (stains clothing/bra without manipulation)

— Unilateral and uniductal

— Bloody, serous, serosanguinous, or clear ("watery")

— Intraductal papilloma (most common cause of pathologic bloody discharge, ~35–50%)

— Duct ectasia

— Fibrocystic change

— DCIS or invasive carcinoma (~5–15% of pathologic discharge)

— Prolactinoma or hypothyroidism (galactorrhea pattern)

Board pearl: The single most important historical screen is asking whether the discharge stains the bra spontaneously. A "yes" answer reclassifies the visit from reassurance to diagnostic imaging and surgical referral, regardless of patient age. Step 3 stems often bury this clue ("noticed spots on her nightgown") to test whether you'll order a mammogram and ultrasound rather than send the patient home.

Nipple discharge is the third most common breast complaint after pain and masses, accounting for ~5% of breast clinic visits and ~7% of breast surgical referrals

Lifetime prevalence is high — up to 50–80% of reproductive-age women can express fluid with manipulation — so the clinical task is separating physiologic from pathologic discharge

Physiologic discharge characteristics:

Pathologic discharge triad (any one feature triggers workup):

Underlying causes range from benign to malignant:

Risk for malignancy rises with: age >40, bloody discharge, associated mass, unilateral single-duct

Galactorrhea is a distinct entity — milky, bilateral, multiductal, non-puerperal — and is an endocrine workup, not a surgical workup

Presentation Patterns and Key History

— Is the discharge from one breast or both? One duct or many?

— Does it occur spontaneously or only with squeezing?

— Color and consistency: bloody, serous (clear), serosanguinous, milky, green, brown, purulent

— Duration, frequency, association with menses

— Associated breast mass, pain, skin or nipple changes

— Amenorrhea or oligomenorrhea, infertility, decreased libido → prolactinoma

— Cold intolerance, fatigue, weight gain, constipation → primary hypothyroidism (elevated TRH stimulates prolactin)

— Headache, bitemporal visual field deficits → pituitary macroadenoma

— Medications: antipsychotics (risperidone, haloperidol), metoclopramide, SSRIs, TCAs, verapamil, opioids, estrogens, H2 blockers, methyldopa

— Recent pregnancy, breastfeeding, abortion, chest wall surgery, herpes zoster of thoracic dermatome

— Cannabis and chronic nipple stimulation

— Unilateral, uniductal, bloody, spontaneous, postmenopausal → papilloma vs DCIS until proven otherwise

— Bilateral, multiductal, milky, amenorrhea → check prolactin and TSH

— Bilateral green/brown, multiductal, perimenopausal → duct ectasia

— Purulent, erythematous, painful, lactating → puerperal mastitis/abscess

Step 3 management: When a patient on risperidone presents with bilateral milky discharge and amenorrhea, do not jump to MRI of the pituitary — check prolactin and TSH first; if prolactin is only mildly elevated (<100 ng/mL) and clearly drug-attributable, coordinate with psychiatry to switch agents (e.g., aripiprazole) before imaging.

Open the history with laterality, spontaneity, and color — these three features alone risk-stratify the visit

Key historical questions:

Galactorrhea-specific history:

Cancer risk factors to elicit: age, family history (BRCA1/2, Lynch), prior chest radiation (e.g., Hodgkin survivors), personal history of atypia or LCIS, age at menarche/menopause, parity, hormone therapy use

Pattern recognition:

Physical Exam Findings and Local Assessment

— Nipple inversion, retraction, eczematous changes (Paget disease)

— Skin dimpling, peau d'orange, erythema, ulceration

— Visible discharge staining the bra or gown

— Asymmetry, contour deformity

— Systematic exam of all four quadrants and tail of Spence, both breasts

— Document any mass: size, location (clock position, distance from nipple), mobility, consistency, tenderness

— Axillary, supraclavicular, infraclavicular lymph node exam

— Apply gentle radial pressure around the areola at each clock position

— Identify the "trigger point" — the single radial site that reproduces discharge

— Determine if discharge emerges from one duct orifice (uniductal) or multiple

— Capture fluid on filter paper or guaiac card; gross blood or hemoccult-positive = pathologic

— Color, volume, spontaneous vs expressed, single duct vs multiple, unilateral vs bilateral

— Subareolar mass + bloody discharge → intraductal papilloma or papillary carcinoma

— Eczematous nipple unresponsive to topical steroids → Paget disease — biopsy, do not keep treating as dermatitis

— Bilateral expressible milk with visual field testing abnormality → suspect macroprolactinoma

— Erythema, fluctuance, fever in non-lactating woman → periductal mastitis (smokers, anaerobes)

Key distinction: A palpable mass with nipple discharge always upgrades the workup — imaging plus tissue diagnosis is mandatory regardless of discharge characteristics, because the mass (not the discharge) now drives the diagnostic algorithm. Conversely, a negative breast exam with pathologic discharge does not allow reassurance — occult DCIS is the classic miss.

Inspection (patient seated, arms at sides, then raised, then hands on hips):

Palpation:

Eliciting the discharge — the highest-yield maneuver:

Document:

Special findings:

Cytology of discharge has poor sensitivity (~35–50%) and is not used to rule out cancer

Diagnostic Workup — Initial Imaging and Labs

Pathway A — Pathologic discharge (unilateral, uniductal, spontaneous, bloody/serous/clear):

— Age ≥30: Diagnostic mammogram + targeted subareolar ultrasound (first-line per ACR Appropriateness Criteria)

— Age <30: Targeted ultrasound first; mammogram added if suspicious or if patient is high-risk

— Pregnant/lactating: Ultrasound first; mammogram safe with abdominal shielding if indicated

— Dilated duct with intraductal mass (papilloma vs DCIS)

— Complex cyst, solid mass, architectural distortion

— Suspicious microcalcifications (segmental, linear branching → DCIS)

— Masses, asymmetries, retroareolar density

Pathway B — Galactorrhea (bilateral, multiductal, milky):

— Serum prolactin (fasting, mid-morning, no recent breast stimulation)

— TSH (hypothyroidism → ↑TRH → ↑prolactin)

— β-hCG (rule out pregnancy)

— BUN/creatinine (CKD impairs prolactin clearance)

— LFTs (cirrhosis)

— Review medication list

— Normal <25 ng/mL (women), <20 (men)

— Mild elevation (25–100) → drugs, hypothyroidism, stalk effect, stress, macroprolactin

— >100 → likely prolactinoma

— >200 → almost certainly prolactinoma (often macroadenoma)

Board pearl: When prolactin is only mildly elevated and clinical suspicion is low, order macroprolactin screening — large, biologically inactive aggregates can falsely elevate the assay and lead to unnecessary MRI. This is a favorite Step 3 distractor.

Workup is bifurcated by discharge type:

Imaging is mandatory regardless of exam findings:

Ultrasound looks for:

Mammogram looks for:

If mammogram + ultrasound are negative but discharge remains pathologic → proceed to contrast-enhanced breast MRI or ductography (galactography); MRI now generally preferred

Cytology of fluid: not routinely recommended (low sensitivity)

Labs:

Prolactin interpretation:

Diagnostic Workup — Advanced and Confirmatory Studies

— Sensitivity for occult DCIS or papilloma ~85–95%

— Identifies multifocal disease and contralateral lesions

— Preferred over ductography, which is technically difficult, painful, and operator-dependent

— MRI is also indicated upfront in high-risk women (BRCA carriers, prior chest XRT, lifetime risk ≥20%)

— Image-guided core needle biopsy (ultrasound- or stereotactic-guided) for any suspicious mass or calcifications

— MRI-guided biopsy for MRI-only lesions

— Indicated when imaging is negative but pathologic discharge persists, or when imaging shows a papillary lesion

— Both diagnostic and therapeutic — resolves discharge in ~90%

— Major duct excision (Hadfield procedure) sacrifices future breastfeeding from that breast — discuss with reproductive-age women

— Prolactin >100 ng/mL without obvious cause

— Persistent galactorrhea with elevated prolactin after drugs/hypothyroidism excluded

— Any visual field deficit, headache, or pituitary symptom regardless of prolactin level

— Confirms microadenoma (<10 mm) vs macroadenoma (≥10 mm)

Step 3 management: A 52-year-old woman with spontaneous unilateral bloody discharge, negative mammogram, and negative ultrasound still requires further evaluation — the correct next step is breast MRI, not reassurance and 6-month follow-up. If MRI is negative and discharge persists, surgical duct excision is the definitive answer, not repeat imaging in 6 months.

Breast MRI with contrast has become the workhorse for pathologic nipple discharge with negative mammogram/ultrasound:

Ductoscopy — direct endoscopic visualization of ducts — available at select centers; not standard of care

Tissue diagnosis options when a lesion is identified:

Surgical duct excision (microdochectomy / major duct excision):

Pituitary MRI with contrast indicated for:

Visual field testing (formal perimetry) for any macroadenoma abutting the optic chiasm

Risk Stratification and First-Line Management Logic

Step 1 — Classify discharge:

— Physiologic (bilateral, multiductal, expressed, non-bloody) → reassure, treat reversible causes

— Pathologic (any of: spontaneous, unilateral, uniductal, bloody/serous/clear) → imaging pathway

— Galactorrhea (bilateral milky, often with menstrual/endocrine symptoms) → endocrine pathway

— Purulent/inflammatory → infection pathway

Step 2 — For pathologic discharge, age-stratify imaging:

— ≥30: mammogram + ultrasound

— <30: ultrasound first

Step 3 — Risk-stratify imaging results (BI-RADS):

— BI-RADS 1–2 (negative/benign) + persistent pathologic discharge → MRI, then duct excision

— BI-RADS 3 (probably benign) → 6-month short-interval follow-up only if discharge resolves; otherwise upgrade workup

— BI-RADS 4–5 → image-guided biopsy

Step 4 — Tissue diagnosis drives management:

— Benign papilloma without atypia: surgical excision often recommended (10–25% upgrade rate at excision)

— Papilloma with atypia or ADH: excision + risk-reduction counseling (consider tamoxifen)

— DCIS / invasive cancer: oncologic management pathway

— Discontinue offending medications when feasible

— Treat hypothyroidism — prolactin often normalizes within weeks of levothyroxine

— Avoid chronic nipple stimulation, tight clothing

— Counsel on stress, chest wall trauma

CCS pearl: In a CCS case of a postmenopausal woman with bloody nipple discharge, the efficient order set is: bilateral diagnostic mammogram, targeted ultrasound, surgical/breast consult all on the same visit. Do not advance the clock waiting for sequential results — Step 3 rewards parallel, not serial, ordering when each test is independently indicated.

Use a structured decision algorithm:

Reversible causes to eliminate before extensive workup (galactorrhea pathway):

Pharmacotherapy — Treating the Underlying Cause

Hyperprolactinemia / prolactinoma:

— Cabergoline — preferred; 0.25–0.5 mg twice weekly, titrate to prolactin and tumor response; better tolerated, more effective than bromocriptine

— Bromocriptine — 1.25–2.5 mg daily, titrate; preferred in pregnancy (more safety data)

— Prolactin every 1 month until normalized, then every 6–12 months

— Repeat pituitary MRI at 3–6 months for macroadenomas, then annually

Drug-induced hyperprolactinemia:

— Risperidone → aripiprazole (partial D2 agonist, minimal prolactin elevation)

— Metoclopramide → ondansetron or domperidone

— SSRI causing problematic symptoms → bupropion or mirtazapine

Hypothyroidism-induced galactorrhea:

Periductal mastitis / subareolar abscess:

Board pearl: A hemodynamically stable patient on cabergoline who develops a new heart murmur needs an echocardiogram to evaluate for valvular regurgitation — a high-yield drug-safety association tested on Step 3.

No drug treats nipple discharge per se — pharmacotherapy targets the underlying etiology

Dopamine agonists are first-line, even for macroadenomas (medical therapy precedes surgery):

Monitor:

Side effects: nausea, orthostasis, headache, psychiatric (impulse control disorders — gambling, hypersexuality), valvular fibrosis at high cumulative cabergoline doses (>3 mg/week)

Stop cabergoline gradually if prolactin normalized and tumor shrunk for ≥2 years (recurrence ~30–50%)

Switch offending agent when possible:

Coordinate with prescribing specialist; do not abruptly stop antipsychotics in psychiatrically unstable patients

Levothyroxine titrated to TSH 0.5–2.5; prolactin and galactorrhea resolve within weeks

Empiric amoxicillin-clavulanate or dicloxacillin + metronidazole (cover anaerobes — smokers)

Image-guided drainage if abscess; recurrent cases need duct excision; smoking cessation is essential

Procedural Management — Duct Excision and Biopsy Techniques

— Ultrasound-guided for masses

— Stereotactic for microcalcifications without sonographic correlate

— MRI-guided for MRI-only lesions

— Indicated when a single trigger duct can be identified preoperatively

— Preserves remaining ducts and potential for breastfeeding

— Cannulation of the trigger duct with methylene blue or lacrimal probe at time of surgery

— Yield: papilloma in 40–60%, duct ectasia in 20–30%, malignancy in 5–15%

— Indicated when trigger duct cannot be localized, multiductal pathologic discharge, recurrent disease, or older patient without fertility concerns

— Removes the entire central ductal complex behind the nipple

— Eliminates breastfeeding from that breast — informed consent issue

— Papilloma without atypia: complete excision sufficient

— Papilloma with atypia (ADH/ALH): excision plus enhanced surveillance; consider chemoprevention

— DCIS: lumpectomy with negative margins + whole-breast radiation, or mastectomy; sentinel lymph node biopsy for mastectomy or high-grade DCIS

— Invasive cancer: full oncologic staging and multidisciplinary management

— Dopamine agonist intolerance or resistance

— Visual deterioration despite medical therapy

— CSF leak from tumor shrinkage

— Patient preference after counseling

Step 3 management: When a 38-year-old woman with a 1.5-cm intraductal papilloma is found on core biopsy to have adjacent atypical ductal hyperplasia, the next step is surgical excision of the entire lesion — ADH on core biopsy carries a 15–30% upgrade rate to DCIS or invasive cancer at excision and is not adequately characterized by needle sampling alone.

Image-guided core needle biopsy is the standard first-line tissue diagnosis for any imaging-detected lesion:

Microdochectomy (single-duct excision):

Major duct excision (Hadfield/central duct excision):

Findings driving subsequent surgery:

Transsphenoidal pituitary surgery for prolactinoma is second-line, reserved for:

Special Populations — Elderly and Renal/Hepatic Impairment

— Lifetime breast cancer risk peaks in this group

— Spontaneous bloody or clear discharge → cancer until proven otherwise

— Mammographic density is lower → mammographic sensitivity is higher

— Threshold for MRI and surgical excision should be low

— Prolactinoma, ectopic prolactin secretion (rare lung/renal tumors), hypothyroidism

— Prolactin is renally cleared — CKD stage 4–5 commonly causes mild hyperprolactinemia (25–100 ng/mL) without pituitary pathology

— Dopamine agonists still effective but start at low dose

— Do not over-image pituitary in dialysis patients with mildly elevated prolactin and no symptoms

— Altered estrogen metabolism may produce gynecomastia and galactorrhea

— Spironolactone (often used for ascites) is a common iatrogenic cause

— Cabergoline metabolized hepatically; reduce dose

— Many on antipsychotics or antiemetics — drug-induced galactorrhea common

— Coordinate medication review with primary prescriber; balance psychiatric stability against cosmetic/endocrine effects

— Document goals of care before pursuing aggressive workup

— Hold warfarin 5 days, DOACs 24–48 hours (renally adjusted), bridge only if high thromboembolic risk (mechanical mitral valve, recent VTE <3 months, CHA₂DS₂-VASc ≥7)

— Aspirin generally can be continued for breast procedures

Key distinction: A mildly elevated prolactin in a dialysis patient on metoclopramide is almost always multifactorial and benign; reflexive pituitary MRI yields incidental findings (pituitary incidentalomas in 10–15% of population) and may trigger an unnecessary cascade. Pursue MRI only with symptoms, prolactin >100, or no reversible cause identified.

Postmenopausal women with any nipple discharge warrant heightened concern:

Galactorrhea in postmenopausal women is distinctly unusual — always investigate:

Chronic kidney disease:

Cirrhosis / hepatic impairment:

Cognitively impaired or institutionalized elderly:

Anticoagulated patients undergoing biopsy or duct excision:

Special Populations — Pregnancy, Lactation, and Adolescents

— Bilateral milky or serous discharge late in pregnancy is physiologic

— Bloody discharge can occur from rapid ductal proliferation ("rusty pipe syndrome") in early lactation — self-limited, but persistence >2 weeks warrants ultrasound

— Pregnancy-associated breast cancer (PABC) — any mass or unilateral pathologic discharge requires workup; ultrasound first, mammogram safe with shielding, MRI without gadolinium if needed

— Core biopsy is safe in pregnancy

— Discontinue cabergoline once pregnancy confirmed (microadenoma); continue bromocriptine if macroadenoma at high risk of growth

— Monitor visual fields each trimester for macroadenomas; do not routinely measure prolactin (physiologically elevated)

— MRI without contrast if symptomatic

— Continue breastfeeding or pumping on affected side

— Dicloxacillin or cephalexin for cellulitis; ultrasound-guided aspiration for abscess

— MRSA coverage (TMP-SMX, clindamycin) for risk factors

— Hormonal fluctuations, OCPs, chest wall stimulation are common causes

— Juvenile papillomatosis — multiple peripheral papillomas, "Swiss cheese" appearance on ultrasound; associated with family history of breast cancer; surgical excision and long-term surveillance

— Avoid mammography; ultrasound is first-line imaging

— Always pathologic — male breast cancer risk; evaluate with mammography and ultrasound regardless of color

— Workup for prolactinoma if bilateral galactorrhea, gynecomastia, hypogonadism

Board pearl: Any bloody nipple discharge in a man is breast cancer until proven otherwise. The Step 3 stem may feature a 60-year-old man with a "small lump under the nipple" and dried blood on his undershirt — answer is diagnostic mammogram and ultrasound, not reassurance.

Pregnancy and lactation:

Prolactinoma in pregnancy:

Postpartum mastitis and abscess:

Adolescents and young women:

Men with nipple discharge:

Complications and Adverse Outcomes

— Up to 15% of pathologic discharges harbor malignancy

— Reassurance based on negative mammogram alone misses occult DCIS; MRI and/or duct excision are essential next steps

— Median time to diagnosis when initial workup is incomplete: 12–24 months — frequent malpractice scenario

— Loss of nipple sensation (~30–40%)

— Nipple inversion or contour deformity

— Inability to breastfeed from that breast (major duct excision)

— Hematoma, seroma, infection

— Persistent or recurrent discharge (~5–10%)

— Impulse control disorders — pathologic gambling, compulsive shopping, hypersexuality (mention to every patient)

— Cardiac valve fibrosis at high cumulative cabergoline doses

— Severe nausea, orthostatic hypotension on initiation

— CSF rhinorrhea from rapid tumor shrinkage (macroadenomas)

— Psychosis exacerbation in vulnerable patients

— Hypogonadism → osteoporosis, infertility, decreased libido

— Macroadenoma growth → visual loss, hypopituitarism

— Persistent galactorrhea → psychosocial distress

— Recurrent abscess

— Mammary duct fistula (Zuska disease) — chronic draining sinus at areolar margin, especially in smokers; requires fistulectomy

— Even after benign diagnosis, persistent worry common — address explicitly

Step 3 management: A patient on cabergoline for 4 years for a microprolactinoma develops new-onset compulsive gambling, dropping savings. The next step is dose reduction or discontinuation of cabergoline and psychiatric referral, not addition of an SSRI — recognizing the drug effect is the testable insight.

Delayed cancer diagnosis is the dominant complication:

Surgical complications of duct excision:

Dopamine agonist complications:

Untreated hyperprolactinemia complications:

Untreated periductal mastitis:

Anxiety and quality-of-life impact:

When to Escalate Care — Consultation and Inpatient Triage

— Any pathologic nipple discharge (spontaneous, unilateral, uniductal, bloody/serous/clear)

— Palpable mass with discharge

— Imaging-detected lesion requiring biopsy

— Recurrent or persistent discharge despite negative imaging

— Suspicious cytology (though cytology is not the gateway)

— Prolactin >100 ng/mL without obvious cause

— Macroprolactinoma

— Dopamine agonist intolerance or resistance

— Suspected MEN1 (consider when prolactinoma plus hyperparathyroidism or pancreatic NET)

— Macroadenoma with visual deficit or apoplexy

— Failure of medical therapy

— CSF leak

— Pituitary apoplexy — sudden severe headache, ophthalmoplegia, visual loss, altered mental status, hypotension from acute adrenal insufficiency → emergency MRI, IV hydrocortisone, neurosurgery

— Severe puerperal abscess with sepsis → IV antibiotics, drainage

— Hemodynamically significant hemorrhage from breast lesion (rare)

— Personal history of breast cancer <50, triple-negative <60, male breast cancer

— Ashkenazi Jewish ancestry with breast/ovarian cancer

— Multiple primaries, bilateral disease, family clustering

CCS pearl: Pituitary apoplexy is a CCS emergency — the correct early orders are stat MRI pituitary, stress-dose hydrocortisone 100 mg IV, IV fluids, urgent neurosurgery consult, ophthalmology consult, electrolytes including sodium. Do not wait for biochemical confirmation of adrenal insufficiency to give steroids.

Breast surgery referral indicated for:

Endocrinology referral for:

Neurosurgery referral for:

Ophthalmology for formal Humphrey visual field testing when chiasmal compression suspected

Inpatient admission rarely required for nipple discharge itself, but consider for:

Genetics referral for:

Lactation consultant for breastfeeding mothers with mastitis or supply concerns

Key Differentials — Same-Category (Intramammary) Causes

— Solitary, central, subareolar, in women 30–50

— Unilateral, uniductal, bloody or serous

— 10–25% upgrade rate to atypia or malignancy at excision

— Multiple peripheral papillomas (papillomatosis) confer higher cancer risk

— Spontaneous bloody or serous unilateral discharge

— Mammogram: segmental, linear-branching microcalcifications

— May have no palpable abnormality

— Discharge with mass, skin changes, or nodal disease

— Usually older patients

— Eczematous, scaling, ulcerated nipple with or without discharge

— Underlying DCIS or invasive cancer in >90%

— Punch biopsy of the nipple for diagnosis — do not treat as dermatitis indefinitely

— Perimenopausal/postmenopausal

— Bilateral, multiductal, green/brown/gray thick discharge

— Often with subareolar tenderness; can mimic infection

— Cyclic bilateral discharge, often clear/green

— Lumpy nodular breast tissue

— Smokers, recurrent subareolar abscesses, mammary duct fistula

— Anaerobic and mixed flora; metronidazole coverage

— Lactating women, milk retention cyst

— Ultrasound shows fat-fluid level

— Seatbelt injury, sports, biopsy site

Key distinction: Color alone does not exclude malignancy. While bloody discharge has the highest cancer association, clear/serous discharge from a single duct also requires full workup — DCIS commonly presents with serous, not bloody, discharge. Step 3 may use clear watery discharge to test this point.

Intraductal papilloma — most common cause of pathologic bloody discharge:

DCIS (ductal carcinoma in situ):

Invasive ductal carcinoma:

Paget disease of the nipple:

Duct ectasia:

Fibrocystic change:

Periductal mastitis / subareolar abscess (Zuska disease):

Galactocele:

Trauma / mammary duct injury:

Key Differentials — Extramammary and Systemic Causes

— Prolactinoma (microadenoma <10 mm, macroadenoma ≥10 mm)

— Primary hypothyroidism — high TRH stimulates lactotrophs

— Acromegaly — GH-secreting adenomas often co-secrete prolactin

— Pituitary stalk effect — non-prolactinoma sellar mass disinhibits prolactin (prolactin usually <150)

— Cushing disease, empty sella, lymphocytic hypophysitis

— Renal cell carcinoma, bronchogenic carcinoma — rare ectopic prolactin

— Gonadotropin-secreting tumors

— CKD → impaired prolactin clearance

— Cirrhosis → altered estrogen metabolism

— Chest wall trauma, thoracotomy, herpes zoster, burns

— Chronic nipple stimulation, breast piercings, ill-fitting garments

— Spinal cord lesions

— Antipsychotics: risperidone, paliperidone, haloperidol > olanzapine > others; aripiprazole least

— Antiemetics: metoclopramide, prochlorperazine, domperidone

— Antidepressants: SSRIs, TCAs, MAOIs

— Antihypertensives: verapamil, methyldopa, reserpine

— GI: H2 blockers (cimetidine), PPIs (uncommon)

— Hormonal: estrogens, OCPs, GnRH agonists

— Opioids, cocaine, cannabis

— Herbal: fenugreek, fennel, anise

Board pearl: Verapamil is the classically tested antihypertensive cause of hyperprolactinemia — when a hypertensive woman on a calcium channel blocker develops galactorrhea, switching to amlodipine (dihydropyridine, does not affect prolactin) is the answer.

Endocrine causes of galactorrhea:

Ectopic hormone production:

Hepatic and renal disease:

Neurogenic stimulation:

Pharmacologic causes (extensive list, common Step 3 stem feature):

Physiologic: pregnancy, lactation, postpartum (up to 1 year after weaning), nipple stimulation, sleep, stress, intercourse, exercise

Secondary Prevention and Long-Term Plan

— Resume age-appropriate screening mammography — biennial age 50–74 (USPSTF 2024 now recommends starting at 40), annual per ACS

— Routine clinical breast exam at primary care visits

— Patient self-awareness counseling (not formal monthly self-exam, which lacks mortality benefit per USPSTF)

— Annual mammography, consider annual breast MRI if lifetime risk ≥20%

— Risk-reduction pharmacotherapy options:

– Premenopausal: tamoxifen 20 mg daily × 5 years (reduces risk ~50%)

– Postmenopausal: raloxifene or aromatase inhibitor (anastrozole, exemestane)

— Counsel risks: tamoxifen → endometrial cancer, VTE, hot flashes; AIs → bone loss, arthralgias

— Lifestyle: weight management, limit alcohol (<1 drink/day), exercise, avoid combined HRT

— Multidisciplinary survivorship plan (oncology, surgery, radiation, primary care)

— Endocrine therapy if hormone receptor-positive

— Annual mammography of remaining breast tissue

— Prolactin every 6–12 months once stable

— MRI annually for macroadenoma until stable, then less frequently

— Bone density (DXA) — hyperprolactinemia and resultant hypogonadism cause osteoporosis

— Consider taper off dopamine agonist after ≥2 years of normal prolactin and tumor regression

Step 3 management: A 45-year-old woman with a recently excised intraductal papilloma found to harbor atypical ductal hyperplasia should be counseled on tamoxifen for 5 years for risk reduction and offered annual MRI + mammogram — both interventions reduce future invasive cancer risk and are board-favored answers.

After benign pathology (papilloma without atypia, duct ectasia, fibrocystic change):

After atypia (ADH, ALH, LCIS) — significant lifetime risk elevation:

After DCIS or invasive cancer:

After prolactinoma treated medically:

Genetic counseling and testing when indicated — informs prophylactic surgery, screening intensity, and family cascade testing

Follow-Up, Monitoring, and Counseling

— Review and discontinue offending medications/behaviors

— Recheck in 3–6 months; resume routine screening

— Re-evaluate immediately if discharge becomes spontaneous, bloody, or unilateral

— Negative workup including MRI: clinical re-evaluation in 3–6 months; persistent symptoms → duct excision

— Post-duct-excision: wound check at 2 weeks, pathology review at 2–4 weeks; resume screening per pathology

— 6-month imaging follow-up of biopsy site for BI-RADS 4A

— Annual mammography thereafter

— Drug-induced: recheck prolactin 1 month after medication change

— Prolactinoma on cabergoline: prolactin every 1 month until normal, then every 3–6 months, then every 6–12 months

— MRI at 3 months (macroadenoma) or 1 year (microadenoma), then annually

— Visual fields every 6–12 months for macroadenomas near chiasm

— DXA at baseline and periodically if hypogonadism present

— Breast self-awareness ("know your normal," report changes)

— Smoking cessation (essential for periductal mastitis, also general cancer risk)

— Alcohol limitation (<1 drink/day reduces breast cancer risk)

— Healthy weight maintenance — postmenopausal obesity raises ER+ cancer risk

— Discussion of family history and genetic risk

— Reproductive plans — duct surgery and breastfeeding implications

CCS pearl: On CCS cases, advancing the clock for follow-up labs and imaging counts for credit — schedule a prolactin and TSH in 4–6 weeks after starting levothyroxine for hypothyroidism-induced galactorrhea, and a breast surgery follow-up at 2 weeks after duct excision. Closing the loop matters.

Physiologic discharge — reassurance pathway:

Pathologic discharge — post-imaging follow-up:

Post-biopsy benign findings:

Hyperprolactinemia monitoring cadence:

Counseling points to document:

Ethical, Legal, and Patient Safety Considerations

— Explicitly discuss loss of breastfeeding capacity from that breast after major duct excision — this is the single most litigated issue

— Document discussion in young/reproductive-age women

— Offer microdochectomy (single-duct) when feasible to preserve function

— Discuss nipple sensation loss, cosmetic outcome, recurrence risk

— Most common malpractice scenario: pathologic bloody discharge with negative mammogram, patient sent home with reassurance, cancer diagnosed 1–2 years later

— Document the three pathologic features assessed, imaging ordered, and follow-up plan

— "Triple test" thinking (exam + imaging + tissue) — when any leg is suspicious or discordant, pursue further evaluation

— Legally documented warning required at initiation — counsel patient and family that compulsive gambling, shopping, and hypersexuality can occur and may cause financial/relationship harm before recognition

— Establish a family contact for safety monitoring

— Shared decision-making with the prescribing psychiatrist before changing antipsychotic

— Do not unilaterally discontinue agents controlling psychosis — risk of decompensation, self-harm

— Coordinate transition of care and follow-up

— While nipple discharge itself is not reportable, suspected non-accidental trauma (chest wall injury patterns in children, intimate partner violence in adults) is a mandatory report

— Document and offer resources

— Avoid gadolinium; counsel risk/benefit of ionizing radiation; obtain consent for any imaging

— Disparities in breast cancer mortality persist; ensure equitable access to MRI, genetic testing, and timely surgical referral regardless of insurance status

Step 3 management: When a patient on risperidone for schizophrenia develops galactorrhea, the ethically correct next step is coordinated discussion with psychiatry about switching to aripiprazole — not unilateral discontinuation of antipsychotic by the primary care physician.

Informed consent for duct excision:

Delayed diagnosis liability:

Cabergoline impulse control disorders:

Drug-induced galactorrhea in psychiatric patients:

Mandatory reporting:

Pregnant patients:

Health equity:

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: If the stem mentions "stained her bra at night," the diagnosis is pathologic discharge and the next step is diagnostic imaging, not reassurance. This single phrase is the most common Step 3 trigger word for this topic.

Pathologic discharge triad: spontaneous + unilateral/uniductal + bloody/serous/clear

Most common cause of pathologic bloody discharge: intraductal papilloma

DCIS can present with clear or bloody unilateral discharge — color does not exclude cancer

Mammogram + ultrasound first imaging in age ≥30 with pathologic discharge

MRI when mammogram + ultrasound negative but discharge pathologic

Cytology of nipple discharge: low sensitivity, not gateway to workup

Paget disease: eczematous nipple → punch biopsy, not topical steroids

Galactorrhea workup: prolactin, TSH, β-hCG, BUN/Cr, medication review

Macroprolactin: false elevation of prolactin assay — screen if mild elevation and asymptomatic

Prolactin >200 ng/mL ≈ prolactinoma (often macro)

Stalk effect: non-prolactinoma sellar mass, prolactin usually <150

Cabergoline > bromocriptine for efficacy/tolerability; bromocriptine preferred in pregnancy

Cabergoline side effects: impulse control disorders, valvular fibrosis (high dose)

Hypothyroidism causes galactorrhea via ↑TRH → ↑prolactin

Risperidone, metoclopramide, verapamil, SSRIs: classic drug causes of hyperprolactinemia

Aripiprazole: antipsychotic least likely to elevate prolactin

Periductal mastitis / Zuska disease: smokers, anaerobes, recurrent subareolar abscess, mammary duct fistula

Duct ectasia: green/brown bilateral multiductal discharge, perimenopausal

Male nipple discharge: always pathologic — workup for malignancy

Atypical ductal hyperplasia on core biopsy: 15–30% upgrade at excision → always excise

Tamoxifen for risk reduction in atypia: 5 years, premenopausal preference; watch endometrial cancer/VTE

High-risk screening (lifetime risk ≥20%): annual MRI + mammogram

BRCA1/2: consider in personal/family history triggers; influences screening, chemoprevention, prophylactic surgery

Pituitary apoplexy: stress-dose hydrocortisone, MRI, neurosurgery — emergency

Board Question Stem Patterns

Key distinction: Step 3 distinguishes "what is the diagnosis?" from "what is the next step?" — the next step is almost always an order (lab, imaging, drug, consult), not a diagnostic label. Read the question stem closely for the imperative.

Stem pattern 1: 52-year-old woman with spontaneous unilateral bloody discharge, normal exam → diagnostic mammogram + ultrasound; if negative → MRI; if still negative and persistent → duct excision

Stem pattern 2: 32-year-old woman, bilateral milky discharge, amenorrhea, infertility → check prolactin, TSH, β-hCG; markedly elevated prolactin → MRI pituitary; treat with cabergoline

Stem pattern 3: Schizophrenic patient on risperidone, bilateral galactorrhea, mildly elevated prolactin → switch to aripiprazole (coordinate with psychiatry); do not order pituitary MRI first

Stem pattern 4: Hypothyroid woman with fatigue, weight gain, milky discharge → start levothyroxine; galactorrhea resolves

Stem pattern 5: 55-year-old smoker, recurrent subareolar abscess, mammary duct fistula at areolar margin → amoxicillin-clavulanate, drainage, and smoking cessation; definitive treatment is duct excision/fistulectomy

Stem pattern 6: 60-year-old man with bloody nipple discharge and small subareolar mass → diagnostic mammogram + ultrasound + core biopsy — male breast cancer

Stem pattern 7: 45-year-old woman with eczematous, scaling nipple unresponsive to topical steroids → punch biopsy for Paget disease

Stem pattern 8: Patient on cabergoline for prolactinoma develops new-onset compulsive gambling → reduce or stop cabergoline, psychiatric referral

Stem pattern 9: Pregnant woman with prior microprolactinoma, now 12 weeks pregnant → discontinue cabergoline; monitor visual fields by trimester

Stem pattern 10: Sudden severe headache, ophthalmoplegia, hypotension in known macroprolactinoma → pituitary apoplexy → IV hydrocortisone, MRI, neurosurgery consult

Stem pattern 11: 38-year-old, ADH on core biopsy of papilloma → surgical excision for upgrade risk; subsequent tamoxifen for risk reduction

Stem pattern 12: Mild prolactin elevation, asymptomatic, found incidentally → rule out macroprolactin before imaging

Stem pattern 13: Postpartum breastfeeding woman with focal red, painful breast and fever → continue breastfeeding, dicloxacillin; abscess on ultrasound → aspirate

One-Line Recap

Nipple discharge is risk-stratified by three features — spontaneity, laterality/duct number, and color — where any pathologic finding (spontaneous, unilateral/uniductal, bloody/serous/clear) mandates diagnostic mammogram plus ultrasound, escalating to MRI and duct excision if discharge persists with negative imaging, while bilateral multiductal milky discharge (galactorrhea) is an endocrine workup starting with prolactin, TSH, and β-hCG.

Board pearl: The single most testable insight is that a negative mammogram does not end the workup for pathologic nipple discharge — MRI and surgical excision remain on the table, and forgetting this is the canonical Step 3 trap.

Pathway split: Pathologic discharge → breast imaging and surgical referral. Galactorrhea → endocrine labs and medication review. Don't mix the algorithms.

Imaging ladder: Mammogram + ultrasound (age ≥30) → MRI if negative and discharge persists → duct excision as both diagnostic and therapeutic endpoint. Cytology has no gateway role.

Endocrine ladder: Rule out pregnancy, hypothyroidism, CKD, medications, and macroprolactin before pituitary MRI. Prolactin >100 (especially >200) with no reversible cause → MRI. Treat prolactinomas with cabergoline first, even macroadenomas; switch to bromocriptine if pregnancy planned.

Cannot-miss diagnoses: DCIS presenting as clear/bloody unilateral discharge, male breast cancer with any discharge, Paget disease masquerading as nipple eczema, pituitary apoplexy in known macroadenoma, atypia upgrade at duct excision.

Step 3 ethos: Document the three pathologic features, order parallel diagnostics, close the follow-up loop, counsel on breastfeeding implications before duct surgery, coordinate medication changes with the prescribing specialist, and remember that reassurance based on a negative mammogram alone is the highest-liability error in this topic.